If You Invested in Haemonetics Corp Mass (HAE)
Looking for the live price? See the HAE quote & overviewWhat $1,000 or $10,000 in HAE Would Be Worth Today
Real historical value by amount invested and how long ago| If you invested | 1 year ago | 5 years ago | 10 years ago | Since Jul 8, 2015 |
|---|---|---|---|---|
| $1,000 | $999 -0% | $1,187 +19% | $2,540 +154% | $1,920 +92% |
| $10,000 | $9,985 -0% | $11,870 +19% | $25,405 +154% | $19,201 +92% |
Based on real historical closing prices through the latest market close. Past performance does not guarantee future results.
Custom Calculation
Choose your own date and amount for HAE$1,000 Investment Over Time
HAE vs S&P 500Year-by-Year Returns
HAE annual performance| Year | Start Price | End Price | Annual Return | Cumulative |
|---|---|---|---|---|
| 2017 | $39.60 | $58.08 | +46.7% | +46.7% |
| 2018 | $63.10 | $100.05 | +58.6% | +152.7% |
| 2019 | $97.30 | $114.90 | +18.1% | +190.2% |
| 2020 | $115.27 | $118.75 | +3.0% | +199.9% |
| 2021 | $119.07 | $53.04 | -55.5% | +33.9% |
| 2022 | $54.70 | $78.65 | +43.8% | +98.6% |
| 2023 | $77.18 | $85.51 | +10.8% | +115.9% |
| 2024 | $85.14 | $78.08 | -8.3% | +97.2% |
| 2025 | $78.40 | $80.15 | +2.2% | +102.4% |
| 2026 | $79.98 | $75.02 | -6.2% | +89.4% |
About Haemonetics Corp Mass
Surgical & Medical Instruments & Apparatus · NYSE
Haemonetics Corporation (NYSE: HAE) is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. According to the company’s own descriptions, its solutions address critical medical needs across hospital settings, plasma collection operations and blood centers. Within the broader manufacturing sector, Haemonetics is associated with surgical and medical instrument manufacturing, focusing on technologies that support blood management, plasma collection and related clinical workflows.
Haemonetics states that its offerings include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients. In addition, the company provides end-to-end plasma collection technologies that are intended to optimize operations for plasma centers. Haemonetics also supplies products that enable blood centers to collect in-demand blood components, aligning with its historical focus on blood and plasma systems.
Based on the business description and segment information provided, Haemonetics’ activities can be viewed across three primary areas: plasma, blood centers and hospital. The Polygon description notes that product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality. This highlights the company’s role in supplying both consumables and devices that support blood and plasma collection and processing.
Haemonetics is incorporated in Massachusetts and lists Boston, Massachusetts as the location of its principal executive offices in recent SEC filings. Its common stock trades on the New York Stock Exchange under the ticker symbol HAE. The company regularly communicates with investors through earnings releases, conference calls and participation in healthcare investment conferences, as reflected in its press releases and Form 8-K filings.
Business segments and focus areas
The Polygon description indicates that Haemonetics operates under three segments: plasma, blood center and hospital. The company emphasizes its plasma and hospital segments due to their growth potential, while the blood center segment is described as facing higher competition. Across these segments, Haemonetics’ product revenue is linked to disposable blood component collection and processing sets and associated equipment.
Company press releases further describe Haemonetics as offering hospital technologies that help advance standards of care and improve outcomes, plasma collection technologies that support plasma center operations, and products that enable blood centers to collect blood components that are in demand. Together, these activities position Haemonetics as a specialist in technologies that support blood and plasma management in clinical and collection environments.
Interventional and vascular closure technologies
Haemonetics has expanded into interventional technologies through its acquisition of Vivasure Medical Limited, as disclosed in a Form 8-K filed on January 9, 2026 and in related press releases. Vivasure is described as a Galway, Ireland-based company pioneering next-generation technology for percutaneous vessel closure. Its PerQseal Elite system uses a proprietary bioabsorbable patch to seal large-bore arteriotomies and venotomies from inside the vessel, offering a sutureless, fully absorbable solution for structural heart and endovascular procedures, according to the acquisition announcement.
The acquisition press release notes that adding Vivasure’s technology expands Haemonetics’ range of closure devices and bolsters its presence in the large-bore closure market. This reflects an extension of Haemonetics’ portfolio into advanced closure products that are intended to support minimally invasive cardiovascular and endovascular procedures. PerQseal and PerQseal Elite are described as not available for sale in the United States in the cited materials.
Regulatory and public company profile
Haemonetics is a publicly traded company subject to U.S. securities regulations and files reports with the Securities and Exchange Commission. Recent Form 8-K filings document events such as quarterly financial results, the acquisition of Vivasure Medical Limited and matters submitted to shareholder votes at the annual meeting. These filings confirm the company’s status as a registrant with a Commission File Number of 001-14041 and identify it as a Massachusetts corporation.
The company regularly announces the timing of its quarterly financial results and hosts conference calls and webcasts with investors and analysts to discuss those results. It also participates in healthcare conferences organized by financial institutions, as indicated by press releases describing presentations at events such as the J.P. Morgan Healthcare Conference and the Goldman Sachs Global Healthcare Conference.
Role in the medical technology and blood management space
Across its communications, Haemonetics consistently describes itself as a global medical technology company focused on addressing critical medical needs. Its activities in hospital technologies, plasma collection and blood center products align with the industry classification of surgical and medical instrument manufacturing. The emphasis on disposable collection and processing sets, related equipment and technologies for plasma centers and hospitals underscores its role in supporting blood and plasma-related procedures and operations.
The acquisition of Vivasure Medical Limited further connects Haemonetics to technologies used in structural heart and endovascular procedures, particularly in the area of large-bore vascular closure. According to the company’s press release, this acquisition is intended to expand its closure device offerings with clinically differentiated technology for arterial and venous access closure.
Stock and investor information
Haemonetics’ common stock is listed on the New York Stock Exchange under the symbol HAE. The company issues press releases to announce earnings availability, conference call details and other material events, and it furnishes these releases as exhibits to Form 8-K filings. Shareholders vote on matters such as the election of directors, advisory approval of executive compensation and the ratification of the independent registered public accounting firm, as documented in the Form 8-K reporting the results of the 2025 Annual Meeting of Shareholders.
FAQs about Haemonetics Corporation (HAE)
Similar Stocks
See how related companies performed
Frequently Asked Questions
Haemonetics Corp Mass investment returns
How much would $1,000 invested in Haemonetics Corp Mass be worth today?
If you invested $1,000 in Haemonetics Corp Mass (HAE) 10 years ago on 2016-07-07, your investment would be worth $2,540 today, representing a +154.0% total return, growing at a compounded rate of 9.8% per year (CAGR).
Has Haemonetics Corp Mass outperformed the S&P 500?
Over the past 10 years, HAE returned +154.0% compared to +258.6% for the S&P 500, underperforming the benchmark by 104.5 percentage points.
What is Haemonetics Corp Mass's average annual return?
The compound annual growth rate (CAGR) of HAE over the past 10 years is 9.8%, growing at a compounded rate each year. Individual years vary significantly — HAE's best recent year was 2018 (+58.6%) and worst was 2021 (-55.5%).
Your Privacy is Protected
This calculator sends the symbol, date, and amount you enter to our server so we can fetch historical market data and render the result. We do not save those entries as a portfolio or account, but standard web server logs may still record the page request.
For informational and educational purposes only — not investment advice.
